Streetbeat News

CYTO

Altamira Therapeutics Ltd.

https://altamiratherapeutics.com

Industry

Biotechnology

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Open

0.50

Mkt cap

1.9M

Volume

35K

High

0.51

P/E Ratio

0.28

52-wk high

17.20

Low

0.48

Div yield

N/A

52-wk low

0.45

Altamira Therapeutics Ltd. (NASDAQ:CYTO) received a letter from Nasdaq indicating non-compliance with the minimum bid price rule, as its stock has traded below $1.00 for 30 consecutive days. The company is not eligible for a cure period due to previous reverse stock splits and plans to appeal the decision.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2024 | 8:05 pm

Altamira Therapeutics has received an extended ISO 13485 certification for its Bentrio nasal spray, indicating compliance with international quality management standards for medical devices.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 1:04 pm

Altamira Therapeutics reported a significant improvement in its H1 2024 earnings, with losses per share decreasing from $(21.55) to $(2.11), marking a 90.21% improvement year-over-year.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:06 pm

Altamira Therapeutics has announced a public offering priced at $0.72 per share, aiming to raise up to $12 million. The offering includes 5.55 million common shares and warrants, with $4 million upfront and potential additional $8 million from milestone-linked warrants.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 9:11 pm

Altamira Therapeutics has expanded its license and distribution agreement with Nuance Pharma for the Bentrio nasal spray. The agreement now includes seven additional countries in East and South East Asia, with a combined population of over 630 million. Nuance Pharma has already launched Bentrio in Hong Kong and is seeking marketing authorization in Mainland China.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:34 pm

Altamira Therapeutics has extended its distribution agreement with Pharma Nordic to include Sweden and Denmark for its Bentrio nasal spray, following a successful launch in Norway.

Portfolio Pulse from Benzinga Newsdesk

August 23, 2024 | 1:04 pm

Lumentum Holdings Inc. (NASDAQ:LITE) shares surged 16.4% after reporting better-than-expected Q4 earnings and strong Q1 revenue guidance. Other notable pre-market movers include SciSparc Ltd. (NASDAQ:SPRC) up 90.1% after court approval for a merger, and Turnstone Biologics Corp. (NASDAQ:TSBX) down 40.5% after poor Q2 EPS results.

Portfolio Pulse from Avi Kapoor

August 15, 2024 | 10:32 am

Altamira Therapeutics' Zbtb46 mRNA nanoparticles have shown significant tumor growth reduction and long-term remission when combined with anti-PD1 therapy, according to results published in Nature Immunology. This highlights the potential to enhance the effectiveness of immune checkpoint inhibitors.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 1:04 pm

Altamira Therapeutics has published preclinical data showing that their SemaPhore nanoparticles delivering SOD2 mRNA significantly reduce aorta dilation, delay rupture, and lower mortality in an animal model of abdominal aortic aneurysm. The positive outcomes suggest potential use in managing small abdominal aortic aneurysms and preventing ruptures.

Portfolio Pulse from Benzinga Newsdesk

July 19, 2024 | 1:03 pm

Altamira Therapeutics has highlighted a review article that discusses the use of Betahistine in managing vertigo. This could potentially impact the company's stock as it brings attention to one of its therapeutic areas.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 1:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.